tesmilifene
Small moleculeexperimental
Tesmilifene, also known as N,N-diethyl-2-(4-phenylmethyl)ethanamine (DPPE), is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed. It reached phase III clinical trials for advanced/metastatic breast cancer before development was discontinued. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2004 (NCT00364754)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCOc1ccc(Cc2ccccc2)cc1- Mol. weight
- 283.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTesmilifene ↗
- ChEMBLCHEMBL26424 ↗
Also known as
- 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine
- 1,2-dipalmitoyl-3-phosphatidylethanolamine
- 1,2-dipalmitoyl-3-phosphatidylethanolamine, ion(1-)
- 1,2-dipalmitoyl-3-phosphatidylethanolamine, (+-)-isomer
- 1,2-dipalmitoyl-3-phosphatidylethanolamine, (r)-isomer
- 1,2-dipalmitoyl-rac-glycerophosphoethanolamine
- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
- (2-(4-benzylphenoxy)ethyl)diethylamine
- bzphoet-diethylammonium chloride
- depmpe
- depmpe
- depmpe
- dhpe
- dipalmitoyl cephalin
- dipalmitoyl phosphatidylethanolamine
- dppe
- dppe
- dppe
- dppe hydrochloride
- ethanamine, n,n-diethyl-2-(4-(phenylmethyl)phenoxy)-, (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alphar*,betas*),11alpha,12alpha,12aalpha,12balpha))-
- n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
- n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
- n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
- n,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine
- n,n-diethyl-2-((4-phenylmethyl)phenoxy)-ethanamine hydrochloride
- n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine hydrochloride
- n,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine hydrochloride
- phosphatidylethanolamine dipalmitoate
- tesmilifene
- tesmilifene
- tesmilifene
- tesmilifene
- tesmilifene
- tesmilifene hydrochloride
- ymb 1002
- ymb 1002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00364195 | Phase 2 | Jun 1, 2006 | YM Biosciences |
| NCT00099281 | Phase 3 | May 1, 2004 | University of Toronto, YM Biosciences |
| NCT00364754 | Phase 1 | May 1, 2004 | YM Biosciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| YM Biosciences | For profit | 3 | 3 | 3 | 2004 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1